Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207 | 0.77 | PPARA (0.46) | KMOPPARAADORA2AADORA1 | |
| SCHEMBL29045053 | 0.76 | PPARA (0.40) | KMOPPARA | |
| SCHEMBL537462 | 0.76 | PPARA (0.40) | KMOPPARAADORA2AADORA1 | |
| SCHEMBL2670725 | 0.76 | PPARA (0.45) | KMOPPARA | |
| SCHEMBL3398203 | 0.74 | KMO (0.47) | KMO | |
| SCHEMBL19356875 | 0.74 | KMO (0.40) | KMOPPARAGPR119ADORA2AADORA1 | |
| SCHEMBL28481167 | 0.74 | RAB9A (0.46) | KMOPPARAADORA2AADORA1 | |
| SCHEMBL1188116 | 0.74 | MEN1 (0.50) | KMOPPARA | |
| SCHEMBL16907809 | 0.74 | NR1H4 (0.44) | KMOPPARA | |
| SCHEMBL2740475 | 0.74 | NPC1 (0.40) | KMOPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | US | claimed |
| EP-3807265-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | Reata Pharmaceuticals, Inc. (US) | 2021-04-21 | — | — | EP | claimed |
| CN-112654610-A | Pyrazole and imidazole compounds for inhibiting IL-17 and ROR gamma | 里亚塔医药公司 | 2021-04-13 | — | — | CN | claimed |
| CN-106414429-B | Pyrazole compounds and their use as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | claimed |
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | claimed |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-19 | — | — | US | claimed |
| US-9932314-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-03 | — | — | US | claimed |
| EP-3152199-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | Actelion Pharmaceuticals Ltd. (CH) | 2017-04-12 | — | — | EP | claimed |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-06 | — | — | US | claimed |
| WO-2015186056-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-10 | — | — | WO | claimed |
| US-11993574-B2 | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma | REATA PHARMACEUTICALS, INC (US) | 2024-05-28 | — | — | US | disclosed |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210147380-A1 | CYSTEINE-DEPENDENT INVERSE AGONISTS OF NUCLEAR RECEPTORS ROR-GAMMA/ROR-GAMMA-T AND METHODS OF TREATING DISEASES OR DISORDERS THEREWITH | REATA PHARMACEUTICALS, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| EP-3810141-A1 | CYSTEINE-DEPENDENT INVERSE AGONISTS OF NUCLEAR RECEPTORS ROR-GAMMA/ROR-GAMMA-T AND METHODS OF TREATING DISEASES OR DISORDERS THEREWITH | Reata Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3807265-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | Reata Pharmaceuticals, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | US | disclosed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | disclosed |
| EP-1259499-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060808-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | KMO 1448/4885PPARA 3322/4885GPR119 1230/4885 |
| US-20210147380-A1 | CYSTEINE-DEPENDENT INVERSE AGONISTS OF NUCLEAR RECEPTORS ROR-GAMMA/ROR-GAMMA-T AND METHODS OF TREATING DISEASES OR DISORDERS THEREWITH | RORC, RORA, RORB | KMO 1424/4885PPARA 40/4885GPR119 276/4885 |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | MMP9, MMP1, MMP3 | KMO 944/4885PPARA 602/4885GPR119 3638/4885 |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | RORC, RORB, RORA | KMO 1412/4885PPARA 122/4885GPR119 299/4885 |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | KMO 1448/4885PPARA 3322/4885GPR119 1230/4885 |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | KMO 1448/4885PPARA 3322/4885GPR119 1230/4885 |
| US-11993574-B2 | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma | RORC, RORB, RORA | KMO 1412/4885PPARA 122/4885GPR119 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.